Menstrual Suppression

Read the new ACOG Clinical Consensus! – General Approaches to Medical Management of Menstrual Suppression

Why menstrual suppression?

  • As an OB/GYN that might sound like a silly question – but for our patients, this is a serious concern!

    • A holdover of understanding (even with the design of OCPs) that a “natural cycle” is necessary for health – it’s not. 

  • Goal overall is to:

    • Reduce menstrual flow, by amount and total days while

    • Find a strategy based on patients preferences and goals, balancing any risk factors.

Which method is best?

  • Combined Hormonal Contraception

    • Can achieve menstrual suppression by skipping the placebo week.

      • Some packs designed for this - 84/7 regimens, 24/4 regimens.

      • This can be done indefinitely!

        • Studies have found these extended cycle and continuous use regimens to be safe and effective

    • Patients should be counseled that over time, breakthrough bleeding is more likely to occur. In a recent RCT comparing OCPs to an LNG-IUD for menstrual suppression, folks in the OCP group had BTB:

      • 50% at pill pack 3;

      • 69% at pill pack 7;

      • 79% at pill pack 13.

    • Bleeding overall tends to decrease with successive cycles.

    • Breakthrough happens less with higher doses of estrogen (i.e., more bleeding on a 20mcg pill than a 30mcg pill).

    • BTB will decrease with each successive cycle – so it’s not unreasonable to consider monthly cycles for 3-6 months, then transition to more extended cycles. 

      • Intermittent estrogen can also be used to help prevent BTB.

    • The patch and vaginal ring can also be used for menstrual suppression, and have advantage of not requiring daily medication.

      • Patch has no difference in frequency of BTB compared to pills.

      • Ring is well tolerated for extended cycles and seems to be effective in reducing/minimizing bleeding.

  • Progestin-Only Methods

    • These can be of particular importance to patients where estrogen is contraindicated (cardiovascular disease, migraine with aura, hypertension, hypercoagulability) or undesired (trans-men, patient preference).

  • POPs

    • The mini-pill (norethindrone 0.35mg) has to be taken in a tight window, and has low rates of amenorrhea, so is generally not a great choice for menstrual suppression.

    • Norethindrone acetate 5mg can be used for menstrual suppression with better success compared to the minipill, with amenorrhea rates of up to 76% at 2 years of use.

      • However, this formulation is not approved as a contraceptive so can’t be used for this.

    • Drosperinone 4mg is a new progestin only pill on the market; data is limited, but it is likely more promising than the minipill for menstrual suppression and also has contraceptive effect. 

      • That said, likely not a first line choice for this indication specifically.

  • DMPA (depot medroxyprogesterone acetate)

    • The DMPA shot is given roughly every 3 months.

    • Amenorrhea rates are good, especially with more prolonged use – 68-71% at 2 years.

      • However, unscheduled bleeding is a common side effect.

      • Loss of bone mineral density and weight gain are other common concerns; the loss of BMD is reversible with discontinuation. 

  • LNG-IUD

    • Excellent at amenorrhea - 50% at 1 year, 60% at 5 years; highest with the 52mg varieties.

    • BTB can be managed by offering a trial of NSAIDs, POPs/OCPs, or doxycycline before discontinuing the IUD.

    • Not a good choice for patients where ovulation suppression is also desired (ie, PCOS) – the IUD has unclear/unpredictable effects on ovulation suppression.

  • Etonogestrel implant (nexplanon)

    • Can be continued up to 5 years for contraception, FDA approved for 3 years.

    • For menstrual suppression, use past 3 years may not be effective. 

    • 22% achieve amenorrhea, but breakthrough bleeding and spotting are common, especially shortly after insertion.

      • BTB can be managed with OCPs or norethindrone.

  • The ACOG document contains a very helpful but large table on the different types of hormonal contraception and their relative success, advantages, and disadvantages with menstrual suppression. Definitely worth keeping a bookmark on or a snapshot on your phone!

How do I go about selecting a method?

  • Counsel your patient with shared-decision making in mind:

    • Be aware of inequities in provision of menstrual suppression methods and your own biases

    • Share with patients realistic expectations of what each method might offer in the way of menstrual suppression

      • No method can guarantee amenorrhea

    • Take into account patient’s preferences and values

    • Be aware of medical history / medical eligibility criteria that might contraindicate certain methods

By patient population:

  • Adolescents:

    • Hormone therapies are safe for adolescents

    • Initiation of menstrual suppression is safe anytime after menarche!

      • Need to have at least one menstrual period to be certain of normal pubertal development.

    • Pelvic exam is not needed for routine prescription of contraception, unless needed for the actual insertion (i.e., IUD)

      • IUD insertion has been shown to not be any more difficult in adolescents compared to older individuals, nor more difficult in nulliparas compared to parous patients.

    • Other tenets of adolescent reproductive healthcare counseling should be applied:

      • Discuss concerns about any side effects that are common / common concerns - fertility, weight, development, bone health, STIs

      • Use the opportunity to establish healthy alignment with adolescent at the OB/GYN office to establish as a safe place for current & future care

  • Transgender / Gender Diverse Patients

    • Menstrual suppression can help reduce feelings of gender dysphoria associated with menstruation

    • Testosterone use for gender-affirming care is associated with amenorrhea, often within a few months of starting therapy.

    • GnRH is also capable of pubertal blockade and suppression of menses for gender-affirming therapy, with amenorrhea rates nearing 100%.

      • Testosterone and GnRH are not contraceptives, though - so if they are at risk of pregnancy, contraception should be discussed

      • GnRH also cannot be used long term given concerns for bone density effects.

  • Patients with physical or cognitive disabilities, or both

    • Particularly for patients with cognitive disability, menstruation is a significant source of anxiety for caregivers and is a common reason for visit for pediatric gynecology clinics, even among premenarchal patients

    • Adolescents and adults with disabilities are also often assumed (erroneously) to be asexual and do not receive sexuality and contraceptive counseling on par with their peers

      • These individuals are also at increased risk of sexual abuse and unintended pregnancy

    • Assist families with developmentally-appropriate education and family assistance with hygiene concerns, contraception, STIs, and abuse prevention

    • Menstrual suppression methods can follow the patient’s needs, preferences, and values. 

      • Consider in these patients their mobility and presence of contractures; swallowing ability for pills; and presence of other interacting drugs (i.e., antiepileptics).

      • If plan for LARC and anesthesia required, it can be considered to “bundle” together services like dental work to minimize patient exposures to anesthetics

    • If patient doesn’t have capacity to make independent decision, menstrual suppression discussions should be made with the caregiver in patient’s best insterest.

      • Ethical and prudent choice is reversible and low-risk options.

  • Populations with challenges affecting hygiene/privacy

    • Military deployment

    • Incarceration

    • Houselessness

    • Patients in war zones or difficulty with care access

    • Athletes

      • Obviously hard to think about all of the potentials here, but consider patient access to medical services, sanitary products, restrooms or private areas, in making shared-decision making on menstrual suppression

How do I manage breakthrough bleeding?

  • One of the most common challenges in menstrual suppression

  • Anticipatory counseling that this is common is helpful in reducing method discontinuation rates and improving method satisfaction, as well as reassuring that BTB is benign and common.

    • Reassure that with some methods BTB decreases or ceases after some time period of initial use